$RNAC

Cartesian Therapeutics (NASDAQ: RNAC) reported Q2 2026 results and a business update. Phase 3 AURORA for Descartes-08 in myasthenia gravis continues, with data expected in 1Q27 and a BLA planned for mid-2027. Phase 2 TRITON myositis and Phase 1/2 HELIOS pediatric trials remain on track for 1H27 data. Cash was $149.3M at June 30, 2026, supporting operations into 2028.

Cartesian Therapeutics, Inc. (RNAC) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 exhibit991_earningsrelease.htm EX-99.1 Document Exhibit 99.1 Cartesian Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update Phase 3 AURORA trial of Descartes-08 in myasthenia gravis (MG) continues to advance; data expected in 1Q27, bio

Cartesian Therapeutics (NASDAQ: RNAC) said it granted inducement stock options to eight new employees on July 1, 2026. The options cover 238,700 shares at a $10.18 exercise price (the Nasdaq close that day). Vesting is 25% on July 1, 2027, then monthly through July 1, 2030; options expire after 10 years.

Cartesian Therapeutics, Inc. (RNAC) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. rnac-20260612 0001453687 false 0001453687 2026-06-12 2026-06-12 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported):

Cartesian Therapeutics (NASDAQ:RNAC) rose after licensing its in vivo CAR-T platform to WestGene, with an upfront payment and potential development/commercial milestones, the company said. The partnership targets a myasthenia gravis trial in 2H 2026 and data in 1H 2027. Shares were about $6.90, up 17.75% Tuesday, per Benzinga Pro. Analysts rate Buy with an average $29.75 target.

Cartesian Therapeutics (NASDAQ: RNAC) said it signed a strategic licensing agreement with WestGene Biopharma to develop in vivo CAR-T therapies for autoimmune diseases, combining WestGene’s targeted LNP delivery with Cartesian’s mRNA payloads from Descartes-08. A Phase 1 dose-escalation study in generalized myasthenia gravis is expected to start in 2H 2026, with data in 1H 2027. WestGene will receive an upfront payment plus potential milestones.

Needham & Company lowered its Cartesian Therapeutics (NASDAQ: RNAC) price target to $40 from $42 while keeping a “buy” rating, according to a Tuesday note reported by Benzinga. RNAC traded at $6.38, down 5.5%. The company reported Q1 EPS of -$1.46 and revenue of $0.08M, missing consensus.

Murat Kalayoglu is resigning from Cartesian's Board of Directors, effective March 31, 2026, to pursue other opportunities. He will also cease serving on the Science and Technology Committee and the Nominating and Corporate Governance Committee. Kalayoglu has been on the board since 2023.

Cartesian Therapeutics, Inc. announced the granting of inducement awards to two new employees. These awards include options to purchase an aggregate of 12,050 shares of the Company's common stock at an exercise price of $6.79. The options will vest over four years, with the first 25% vesting on February 2, 2027, and the remainder vesting in monthly installments.

Cartesian Therapeutics, Inc. ( NASDAQ:RNAC ) on Friday shared initial data from the ongoing Phase 2 open-label trial of Descartes-08, its lead cell therapy candidate, for systemic lupus erythematosus ( SLE ) .